Search

Your search keyword '"M Thill"' showing total 10 results
Start Over Author "M Thill" Publisher elsevier bv
10 results on '"M Thill"'

3. LBA14 Impact of age, recurrence score (RS) and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Analysis of ADAPT and ADAPTcycle trials

Author

O. Gluz, U.A. Nitz, M. Christgen, S. Kuemmel, M. Braun, M. Thill, B. Aktas, P. Wimberger, K. Luedtke-Heckenkamp, M. Zaiss, M. Warm, C. Schumacher, C. Schem, M. Graeser, A.D. Hartkopf, R.E. Kates, C. zu Eulenburg, P. Schmid, H. Kreipe, and N. Harbeck

Subjects
Oncology, Hematology
Published
2022
Full Text
View/download PDF

6. 120P AXSANA (AXillary Surgery After NeoAdjuvant Treatment) EUBREAST-3: An international prospective multicenter cohort study to evaluate different surgical methods of axillary staging in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy (NCT04373655)

Author

F. Ruf, T. Kühn, S. Hartmann, J. de Boniface, O.D. Gentilini, E. Stickeler, G.K. Cakmak, I. Rubio, L. Niinikoski, M. Kontos, D. Murawa, E-A. Bonci, M. Hauptmann, M. Thill, H. Markus, M.P. Lux, M. Appelgren, J-U. Blohmer, M. Untch, and M. Banys-Paluchowski

Subjects
Oncology, Hematology
Published
2022
Full Text
View/download PDF

8. 94P Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC)

Author

M. Reinisch, J-U. Blohmer, T. Link, M. Just, M. Untch, O. Stötzer, P.A. Fasching, A. Schneeweiss, P. Wimberger, S. Seiler, J. Huober, M. Thill, C. Jackisch, K. Rhiem, C. Solbach, C. Hanusch, C. Denkert, K. Engels, V. Nekljudova, and S. Loibl

Subjects
Oncology, Hematology
Published
2022
Full Text
View/download PDF

10. Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry

Author

E, Laakmann, I, Witzel, T, Neunhöffer, T-W, Park-Simon, R, Weide, K, Riecke, A, Polasik, M, Schmidt, J, Puppe, C, Mundhenke, K, Lübbe, T, Hesse, M, Thill, D-M, Zahm, C, Denkert, T, Fehm, V, Nekljudova, J, Rey, S, Loibl, and V, Müller

Subjects
Cancer Research, Oncology, Brain Neoplasms, Receptor, ErbB-2, Humans, Breast Neoplasms, Female, Registries
Abstract

Up to 40% of patients with metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer develop brain metastases (BMs). Understanding of clinical features of these patients with HER2-positive breast cancer and BMs is vital.A total of 2948 patients from the Brain Metastases in Breast Cancer registry were available for this analysis, of whom 1311 had primary tumors with the HER2-positive subtype.Patients with HER2-positive breast cancer and BMs were-when compared with HER2-negative patients-slightly younger at the time of breast cancer and BM diagnosis, had a higher pathologic complete response rate after neoadjuvant chemotherapy and a higher tumor grade. Furthermore, extracranial metastases at the time of BM diagnosis were less common in HER2-positive patients, when compared with HER2-negative patients. HER2-positive patients had more often BMs in the posterior fossa, but less commonly leptomeningeal metastases. The median overall survival (OS) in all HER2-positive patients was 13.2 months (95% confidence interval 11.4-14.4). The following factors were associated with shorter OS (multivariate analysis): older age at BM diagnosis [≥60 versus60 years: hazard ratio (HR) 1.63, P0.001], lower Eastern Cooperative Oncology Group status (2-4 versus 0-1: HR 1.59, P0.001), higher number of BMs (2-3 versus 1: HR 1.30, P = 0.082; ≥4 versus 1: HR 1.51, P = 0.004; global P = 0.015), BMs in the fossa anterior (HR 1.71, P0.001), leptomeningeal metastases (HR 1.63, P = 0.012), symptomatic BMs at diagnosis (HR 1.35, P = 0.033) and extracranial metastases at diagnosis of BMs (HR 1.43, P = 0.020). The application of targeted therapy after the BM diagnosis (HR 0.62, P0.001) was associated with longer OS. HER2-positive/hormone receptor-positive patients showed longer OS than HER2-positive/hormone receptor-negative patients (median 14.3 versus 10.9 months; HR 0.86, P = 0.03), but no differences in progression-free survival were seen between both groups.We identified factors associated with the prognosis of HER2-positive patients with BMs. Further research is needed to understand the factors determining the longer survival of HER2-positive/hormone receptor-positive patients.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results